NEW YORK, April 29, 2025--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance(1). NEW YORK, April 26, 2025--Pfizer Inc ...

The 16th Philippine SME Business Expo and Conference opens with a ribbon cutting with VIPs from the Philippine and International business communities. The 16th Philippine SME Business Expo (PHILSME ...

In the Philippines, few developments reflect this shift more clearly than the Mall of Asia (MOA) complex in Pasay City. Across a single district, MOA brings together a rare convergence ...

The BREAKWATER trial showed improved response rates and survival with Braftovi, Erbitux, and chemotherapy in BRAF V600E-mutated metastatic colorectal cancer. FDA approval in December 2024 highlights ...

Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza Della Scienza 2, 20126 Milan, Italy ...

Its oncology revenues grew 7% on an operational basis in the first quarter of 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. Pfizer has ventured into the ...

Dr. Cathy Eng discusses the importance of the Braftovi plus Erbitux FDA approval for treatment-naive BRAF V600E+ metastatic colorectal cancer. In December 2024, the United States Food and Drug ...

"LUT014 0.1% gel provides statistically significant benefit over placebo gel for the treatment of acneiform rash associated with cetuximab (Erbitux) or panitumumab (Vectibix) therapy for patients ...

Most of us probably remember the time when we heard about the little boy who was thrown off the balcony on the third floor at the Mall of America. It happened six years ago as the little boy and his ...

KRYSTAL-1 is an open-label, nonrandomized, multiple-expansion cohort phase 1/2 trial evaluating the safety and efficacy of the combination of adagrasib and cetuximab in patients with advanced KRAS ...